Search Medical Condition
Please enter condition
Please choose location from dropdown

Atrial Fibrillation Clinical Trials

A listing of Atrial Fibrillation medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (404) clinical trials

Eligibility Criteria: Once you have decided to participate and have learned of the details of the trial you will be seen and evaluated for the following: To be eligible to participate you will be evaluated for Severity of aortic stenosis. You must meet criteria for heart team agreement of low …

Phase

Eligibility Criteria: Inclusion Criteria:•Age > or equal to 18 years of age•History of non-paroxysmal form of AF as defined by the HRS/EHRA/ECAS Consensus Statement:◦Persistent AF shall be defined as continuous AF that is sustained beyond seven days. Episodes of AF in which a decision is made to electrically or pharmacologically …

Phase

Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..

Post-authorization observational, prospective, follow-up study of a cohort of patients with non-valvular atrial fibrillation treated with direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) to assess the clinical course (occurrence of stroke, other ischemic or bleeding events and mortality) and its correlation with clinical, pharmacokinetic (plasma concentrations), pharmacodynamic (haemostatic) and …

Phase N/A

EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality

This multi-centre real-world study will recruit patients across different National Health Service (NHS) sites based in England, where the overall patient population demographic profile is sufficiently variable to allow for meaningful representation of different ethnicities in the analysis of pooled data-sets. The study addresses the issue of health inequality and …

Phase N/A

PLUG Dementia Trial

Patients will be screened at Intermountain Medical Center and at Intermountain affiliated anticoagulation clinics in the Salt Lake City region. Patients with atrial fibrillation that undergo a standard of care, clinically approved, left atrial appendage closure will be considered for study. All patients will be followed for 24 months, and …

Phase N/A

Cognitive Impairment in Atrial Fibrillation

Background: AF is mostly a disease of elderly. Up to 10% of people aged 80 years or older suffer from this arrhythmia and the rate is projected to triple in the next 20 years (1). Evidence is emerging that AF may increase the risk of all forms of dementia (2). …

Phase N/A

Prospective Study to Validate Ablation Parameters With MRI Based Scar for Left Atrial Ablation

A critical step to improve atrial fibrillation (AF) ablation broadly is to minimize interoperator variability. VISITAG SURPOINT calculated a marker tag index value by combining contact force, power setting, and duration of energy delivered. Use of VISITAG SURPOINT has accurately predicted sites of pulmonary vein reconnection and regional changes in …

Phase N/A

AMPLATZER LAA Occluder Post Approval Study (PAS)

The AMPLATZER LAA Occluder device will be clinically evaluated through this post approval study. This is a non-randomized multicenter study on patients who have undergone a procedure to implant an AMPLATZER LAA Occluder or will undergo an implant of an AMPLATZER LAA Occluder.

Phase N/A

Inflammation Fibrosis and Risk of Recurrence After Atrial Fibrillation Ablation

The prevalence of atrial fibrillation (AF) is on the rise, being the most frequent sustained supraventricular arrhythmia and a health issue by its increased morbidity and mortality. In most of the cases, myocardial tissue located at the level of the pulmonary veins represents the trigger for atrial fibrillation. The pathophysiology …

Phase N/A

Safety of Terminating the Prescription of Aspirin After Left Atrial Appendage Closure

The STOP ASPIRIN trial is a prospective, multi-center, randomized, double blinded, placebo-controlled study aiming at investigating the safety of terminating the use of aspirin since the sixth month after left atrial appendage closure (LAAC). Patients diagnosed with paroxysmal or persistent atrial fibrillation with an age between 18 and 90 years …

Phase N/A